Skip to content
Bomb Report – Lifestyle
Author:
Paytronix Systems Inc.
Gift Card Industry Sees Revenue Surge Amid Consumer Shift Toward Higher Value Cards, Paytronix Data Reveals
November 5, 2026
Paytronix Announces Access Evo with Guest Intelligence for Greater Visibility into Guest Behavior
October 7, 2026
Paytronix Introduces Messaging to Access Evo to Help Brands Measure and Act on What Brings Guests Back
September 15, 2026
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
August 19, 2026
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
August 12, 2026
Paytronix Announces Winners of the 2026 Loyaltees Awards; Rewarding the Best in C-Store and Restaurant Programs
August 4, 2026
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
July 28, 2026
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
July 23, 2026
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
July 13, 2026
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
July 6, 2026
1
2
Next Page
→